Lantheus Medical Imaging and GE Healthcare have signed a term sheet for the continued development of flurpiridaz F 18, an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease. {read more here}